The Naproxen Theory: Researchers Poke Holes In Merck Vioxx Defense
This article was originally published in The Tan Sheet
Executive Summary
Naproxen's limited cardioprotective effect relative to aspirin makes it an inadequate explanation for Merck's delay in recalling Vioxx from the market, according to Gurkirpal Singh, MD, Stanford University
You may also be interested in...
Reversal Of Fortune? Vioxx Recall Presents Opportunity For NSAID Makers
OTC NSAID manufacturers could be the indirect beneficiaries of Merck's decision to initiate a worldwide recall of its COX-2 inhibitor Vioxx (rofecoxib)
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands